Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Signs on as First Partner for BioWisdom's Toxicity Safety Program

NEW YORK (GenomeWeb News) - AstraZeneca has signed a three-year agreement for BioWisdom’s Safety Intelligence Program, an initiative to develop an “intelligence system” to analyze drug safety and toxicity data for use in drug discovery and development.
 
BioWisdom said AstraZeneca is its first partner for the program, and as such takes a place on the firm’s SIP advisory board. 
 
The SIP program will support development of methods for identifying and analyzing toxicities, characterizing mechanisms of protein targets with toxic effects, predicting and evaluating potential toxicity issues, comparing species for animal models, and planning and designing clinical trials, BioWisdom said.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.